Overview

A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-06-09

Target enrollment:

Participant gender:

Summary

The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and docetaxel combination therapy in participants with metastatic non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection); and to evaluate the antitumor effect of the combination at the selected RP2CD in participants with NSCLC without oncogenic driver mutations with disease progression on platinum-based chemotherapy and immune checkpoint inhibitor, in the Phase 2 (expansion).

Phase:

PHASE1

Details

Lead Sponsor:

Janssen Research & Development, LLC

Treatments:

amivantamab
Docetaxel